Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers
oleh: Sherille D. Bradley, Amjad H. Talukder, Ivy Lai, Rebecca Davis, Hector Alvarez, Herve Tiriac, Minying Zhang, Yulun Chiu, Brenda Melendez, Kyle R. Jackson, Arjun Katailiha, Heather M. Sonnemann, Fenge Li, Yaan Kang, Na Qiao, Bih-Fang Pan, Philip L. Lorenzi, Mark Hurd, Elizabeth A. Mittendorf, Christine B. Peterson, Milind Javle, Christopher Bristow, Michael Kim, David A. Tuveson, David Hawke, Scott Kopetz, Robert A. Wolff, Patrick Hwu, Anirban Maitra, Jason Roszik, Cassian Yee, Gregory Lizée
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2020-10-01 |
Deskripsi
Cytotoxic T lymphocyte (CTL)-based immunotherapies can induce tumor regressions by targeting HLA class I-bound tumor-associated peptides. Here, the authors identified a peptide derived from Vestigial-like 1 (VGLL1) as a shared, potentially therapeutic CTL target expressed by multiple cancer types.